Rentschler Biopharma Inc.
27 Maple Street
About Rentschler Biopharma Inc.
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO), focused exclusively on client projects. From its headquarters in Laupheim, Germany and its site in Milford, MA, USA, Rentschler Biopharma offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,000 employees. For more information, please visit www.rentschler-biopharma.com and for business development related information, please visit www.business.rentschler-biopharma.com
48 articles with Rentschler Biopharma Inc.
Rentschler Biopharma and Vetter, two globally operating Contract Development and Manufacturing Organizations, announced that their strategic collaboration has taken key steps forward.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Rentschler Biopharma appoints Dr. Martin Kessler as Chief Executive Officer of U.S. Subsidiary and as Senior Vice President Transformation
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Dr. Martin Kessler as Chief Executive Officer of Rentschler Biopharma Inc., the Company’s wholly owned U.S. subsidiary, and as Senior Vice President Transformation of Rentschler Biopharma SE, effective March 1, 2021.
Leukocare joins Rentschler Biopharma in the U.S., facilitating integrated alliance capabilities and enhanced service for North American clients
Rentschler Biopharma will establish their ATMP development and manufacturing capabilities at the Cell and Gene Therapy Catapult facility in Stevenage
New enterprise, Rentschler ATMP Ltd., is part of continuous innovation at Rentschler Biopharma and supports ongoing strategic international expansion
Rentschler Biopharma and ATUM Announce Leap-In Transposase® Licensing Agreement for Development of Robust Manufacturing Processes for Complex Therapeutic Proteins
License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools
Joining Forces Against SARS-COV-2: Rentschler Biopharma Contributes to Manufacturing of COVID-19 mRNA Vaccine
Rentschler Biopharma to provide cGMP manufacturing services for mRNA-based vaccine candidate, developed by BioNTech and Pfizer against SARS-CoV-2
Rentschler Biopharma and Vetter Team up With Joint Goal to Simplify Processes and Optimize Time-to-market
Vetter and Rentschler Biopharma, two globally operating Contract Development and Manufacturing Organizations, announced their strategic collaboration, to enhance their services and offer complementary skills and experience along the biopharmaceutical value chain.
6/19/2020Biopharma and life sciences companies bolster their executive leadership teams and boards with these Movers & Shakers.
Rentschler Biopharma SE, a leading global contract development and manufacturing organization for biopharmaceuticals, announced the appointment of Alexander Dettmer as Chief Financial Officer, effective July 1, 2020.
Innovative agreement provides flexible model to address Genmab’s development and manufacturing needs as programs advance in development Rentschler Biopharma’s U.S. site expansion progressing on track with plans to significantly increase square footage and number of employees
Rentschler Biopharma Licenses Horizon Discovery’s CHOSOURCE Platform to Complement Cell Line Development Offering for Difficult-To-Express Proteins
CHOSOURCE platform to be combined with Rentschler Biopharma’s novel in-house cell line development process to provide speed, stability and high yield
As the biopharma industry responds to the COVID-19 pandemic, some of the area's companies are at the very frontlines of drug development against the disease, while others play supporting roles for the entire industry. Here's a look.
Rentschler Biopharma SE, a world-class contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced the hiring of two executives for its facility in Milford, MA, USA, in the greater Boston area.
Company’s clinical and commercial manufacturing capabilities to be showcased during BIO-Europe® , November 11-13 in Hamburg, Germany
Rentschler Biopharma management duo Nikolaus F. Rentschler and Frank Mathias recognized as "EY Entrepreneur of the Year"
Rentschler Biopharma SE, a world-class contract development and manufacturing organization for biopharmaceuticals, announced that its Chairman of the Board, Prof. Dr. Nikolaus F. Rentschler, together with CEO Dr. Frank Mathias have received the "EY Entrepreneur of the Year" Award 2019 in the category Industry.
Rentschler Biopharma SE, a world-class contract development and manufacturing organization for biopharmaceuticals, has been featured on the annual list of Germany’s best employers for the second year in a row.
Rentschler Biopharma Announces Enhanced Collaboration with Summit Pharmaceuticals International Corporation to Expand Japanese Operation-Base
Company also announces participation in BioJapan 2019, one of Asia’s largest partnering events for the global biotechnology industry, October 9-11, 2019 in Pacifico Yokohama
Rentschler Biopharma SE appoints Henning Gerschewski as Vice President Manufacturing Science and Technology
Rentschler Biopharma SE announced today that Henning Gerschewski (44) will join the company as Vice President Manufacturing Science and Technology, effective January 01, 2019. He will head a highly experienced team of senior scientists with the goal of ensuring technical leadership in process development and technology transfer activities.